| Literature DB >> 34082811 |
Huaili Jiang1,2, Lei Zhou1,2, Qiangsheng He3,4, Kanglun Jiang1,2, Jinqiu Yuan5,6, Xinsheng Huang7,8.
Abstract
BACKGROUND: There are limited evidences clarifying the impact of metabolic syndrome (MS) and its components on head and neck cancer (HNC) incidence risk. We explored the correlation between MS, MS components, and the combined effects of MS and C-reactive protein (CRP) and HNC risk.Entities:
Keywords: C-reactive protein; Head and neck cancer; Metabolic syndrome; Metabolic syndrome components
Year: 2021 PMID: 34082811 PMCID: PMC8173864 DOI: 10.1186/s40170-021-00261-w
Source DB: PubMed Journal: Cancer Metab ISSN: 2049-3002
Baseline characteristics of participants according to MS in the UK biobank cohort
| Metabolic syndrome (N) | No ( | Yes ( |
|---|---|---|
| 6.58 (1.23) | 6.49 (1.30) | |
| 55.5 (8.15) | 58.3 (7.64) | |
| 25.9 (3.86) | 31.0 (4.90) | |
| 85.8 (11.3) | 101 (12.1) | |
| 1.55 (0.366) | 1.22 (0.303) | |
| 1.44 (0.777) | 2.42 (1.19) | |
| 4.88 (0.671) | 5.63 (1.87) | |
| 137 (19.7) | 146 (17.9) | |
| 80.9 (10.6) | 85.4 (10.3) | |
| Larynx | 61 | 42 |
| Tonsil | 92 | 42 |
| Oral cavity | 181 | 111 |
| Nasal cavity and sinuses | 16 | 6 |
| Oropharynx | 14 | 7 |
| Hypopharynx | 20 | 4 |
| Others | 111 | 99 |
| Female | 188906 (56.5%) | 66956 (47.7%) |
| Male | 145677 (43.5%) | 73390 (52.3%) |
| College or University degree | 117845 (35.2%) | 35265 (25.1%) |
| Other | 162865 (48.7%) | 70220 (50.0%) |
| unknown/missing | 53873 (16.1%) | 34861 (24.8%) |
| White | 315381 (94.3%) | 131082 (93.4%) |
| Non-White | 17645 (5.3%) | 8492 (6.1%) |
| unknown/missing | 1557 (0.5%) | 772 (0.6%) |
| 1th | 61047 (18.2%) | 20643 (14.7%) |
| 2th | 59990 (17.9%) | 21823 (15.5%) |
| 3th | 58520 (17.5%) | 23158 (16.5%) |
| 4th | 56301 (16.8%) | 25571 (18.2%) |
| 5th | 52601 (15.7%) | 29330 (20.9%) |
| Missing | 46124 (13.8%) | 19821 (14.1%) |
| Current | 34587 (10.3%) | 15915 (11.3%) |
| Previous | 107678 (32.2%) | 54704 (39.0%) |
| Never | 190793 (57.0%) | 68809 (49.0%) |
| Unknown/missing | 1525 (0.5%) | 918 (0.7%) |
| Daily or almost daily | 72332 (21.6%) | 23976 (17.1%) |
| 1–4 times a week | 169384 (50.6%) | 62723 (44.7%) |
| One to three times a month | 35496 (10.6%) | 17363 (12.4%) |
| Special occasions only or never | 56642 (16.9%) | 35901 (25.6%) |
| Unknown/missing | 729 (0.2%) | 383 (0.3%) |
| Low | 44878 (13.4%) | 26981 (19.2%) |
| Moderate | 109466 (32.7%) | 45595 (32.5%) |
| High | 117170 (35.0%) | 37074 (26.4%) |
| Unknown/missing | 63069 (18.9%) | 30696 (21.9%) |
| 4.66 (3.11) | 4.52 (3.16) | |
| No | 209520 (62.6%) | 67714 (48.2%) |
| Yes | 117629 (35.2%) | 70322 (50.1%) |
| Missing | 7434 (2.2%) | 2310 (1.6%) |
| No | 145619 (43.5%) | 30015 (21.4%) |
| Yes | 161311 (48.2%) | 106964 (76.2%) |
| Missing | 27653 (8.3%) | 3367 (2.4%) |
Risk of head and neck cancer according to MS and its components
| No of cases/person-years | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | HR (95%CI) | |||||
| No | 495/ 2201184 | Reference | Reference | Reference | |||
| Yes | 311/ 910374 | 1.05[0.90, 1.22] | 0.560 | ||||
| 0–2 | 483/2167132 | Reference | Reference | Reference | |||
| 3 | 191/582520 | 1.14[0.96, 1.35] | 0.126 | 1.04[0.88, 1.24] | 0.645 | ||
| 4 | 95/283291 | 1.16[0.93, 1.45] | 0.187 | 1.00[0.80, 1.26] | 0.978 | ||
| 5 | 37/78614 | 1.30[0.92, 1.84] | 0.132 | ||||
| No | 500/2065978 | Reference | Reference | Reference | |||
| Yes | 304/1036668 | 1.10[0.95, 1.26] | 0.211 | 1.04[0.90, 1.21] | 0.592 | ||
| No | 141/845849 | Reference | Reference | Reference | |||
| Yes | 665/2262915 | 1.06[0.91, 1.23] | 0.461 | 0.95[0.81, 1.10] | 0.472 | ||
| No | 301/1501095 | Reference | Reference | Reference | |||
| Yes | 464/1438442 | 1.16[0.98, 1.39] | 0.091 | 1.17[0.98, 1.39] | 0.087 | 1.01[0.84, 1.22] | 0.877 |
| No | 528/2095502 | Reference | Reference | Reference | |||
| Yes | 160/568287 | 1.02[0.84, 1.22] | 0.874 | 1.00[0.82, 1.20] | 0.973 | ||
| No | 529/2226708 | Reference | Reference | Reference | |||
| Yes | 174/459089 | ||||||
Model 1: unadjusted
Model 2: age and gender-stratified model
Model 3: additionally adjusted for education, ethnic, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP
Fig. 1The non-linear effect between individual MS components and HNC risk. A Waist circumference, B waist circumference for males, C waist circumference for females, D HDL-C (high-density lipoprotein-cholesterol), E HDL-C for males, F HDL-C for females, G blood glucose, H SBP (systolic blood pressure), I DBP (diastolic blood pressure), J TG (triglyceride)
Linear associations for MS components related to head and neck cancer risk
| MS components | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| Waist circumferencea | ||||||
| Waist circumference (male) | ||||||
| Waist circumference (female)b | 0.98[0.85, 1.13] | 0.788 | 0.98[0.85, 1.13] | 0.796 | 0.95[0.82, 1.10] | 0.490 |
| HDL-Ca | 1.02[0.93, 1.11] | 0.723 | 1.07[0.98, 1.17] | 0.098 | ||
| HDL-C (male)b | 1.01[0.93, 1.10] | 0.801 | 1.01[0.93, 1.10] | 0.783 | 1.05[0.97, 1.15] | 0.243 |
| HDL-C (female)b | 1.02[0.87, 1.18] | 0.830 | 1.02[0.88, 1.18] | 0.821 | 1.08[0.92, 1.27] | 0.329 |
| Blood glucoseb | ||||||
| Diastolic blood pressureb | 0.99[0.92, 1.06] | 0.716 | 0.99[0.93, 1.07] | 0.848 | ||
| Systolic blood pressure | 1.03[0.96, 1.11] | 0.415 | 1.03[0.96, 1.10] | 0.451 | ||
| Triglycerides (mmol/L) | 1.03[0.97, 1.11] | 0.339 | 0.97[0.91, 1.04] | 0.407 | ||
Model 1: unadjusted
Model 2: age and gender-stratified model
Model 3: additionally adjusted for education, ethnic, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP
aMS component with sex-specific definition
bU-shaped association MS components related to head and neck cancer risk in non-linear spline models
Linear associations for MS components with U-shaped relation to head and neck cancer risk
| MS components | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| Waist circumference (female) | ||||||
| <93.16 cm | 0.94[0.80, 1.11] | 0.469 | 0.94[0.80, 1.11] | 0.471 | 0.92[0.78, 1.08] | 0.311 |
| ≥93.16 cm | ||||||
| HDL-C (male) | ||||||
| <1.26 mmol/L | ||||||
| ≥1.26 mmol/L | ||||||
| HDL-C (female) | ||||||
| <1.45 mmol/L | 0.90[0.70, 1.14] | 0.384 | 0.90[0.70, 1.14] | 0.381 | 0.91[0.71, 1.17] | 0.462 |
| ≥1.45 mmol/L | 1.05[0.88, 1.27] | 0.576 | 1.05[0.88, 1.27] | 0.567 | 1.10[0.92, 1.33] | 0.301 |
| Blood glucose | ||||||
| <4.70 mmol/L | 0.93[0.80, 1.08] | 0.330 | 0.97[0.84, 1.12] | 0.674 | 0.96[0.83, 1.11] | 0.577 |
| ≥4.70 mmol/L | ||||||
| Diastolic blood pressure | ||||||
| <83 mmHg | 1.07[0.96, 1.18] | 0.221 | 1.09[0.98, 1.21] | 0.121 | ||
| ≥83 mmHg | 1.03[0.94, 1.14] | 0.538 | 0.99[0.90, 1.10] | 0.917 | 0.99[0.90, 1.09] | 0.886 |
Model 1: unadjusted
Model 2: age and gender-stratified model
Model 3: additionally adjusted for education, ethnic, Index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP
Risk of head and neck cancer according to CRP and the joint effect of MS and CRP
| No. of cases/person-years | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| CRP | |||||||
| < 1.00 mg/dL | 223/1155432 | Reference | Reference | Reference | |||
| ≥ 1.00 mg/dL | 531/1750092 | ||||||
| Joint effect of MS and CRP | p-interaction=0.501 | ||||||
| No MS/CRP < 1.00 mg/dL | 181/1027524 | Reference | Reference | Reference | |||
| No MS/CRP ≥ 1.00 mg/dL | 327/1153876 | ||||||
| MS/CRP < 1.00 mg/dL | 42/127908 | 1.30[0.93, 1.82] | 0.126 | 1.20[0.85, 1.68] | 0.298 | ||
| MS/CRP ≥ 1.00 mg/dL | 204/596216 | ||||||
Model 1: unadjusted
Model 2: age and gender-stratified model
Model 3: additionally adjusted for education, ethnic, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, and NASIDS use